Clair Health Raises $11.6M to Launch Hormone Monitor

The big picture: Clair Health, a San Francisco-based startup, has raised $11.6 million in seed funding led by Khosla Ventures. The company plans to launch the first noninvasive, continuous hormone monitor for women in November 2026.

Why it matters:

• Underserved Market: Women’s health has historically been underrepresented in clinical trials, and current wearable technology often overlooks the complexities of hormonal cycles.
• Inaccurate Tracking: Existing wearables and cycle-tracking apps rely on assumptions or calendar-based predictions, failing to account for individual hormonal fluctuations or irregular cycles in 30% of women.
• Data Gap: A significant gap exists in continuous, noninvasive physiological data for women’s hormone health, leading to incomplete health insights and reactive rather than preventative care.

How it works:

• Multi-sensor Approach: Clair’s device uses 10 biosensors and over 130 proprietary biomarkers to continuously measure estrogen, progesterone, LH, and FSH.
• Noninvasive Monitoring: The system operates without blood draws, urine tests, or needles, collecting signals from multiple sources simultaneously to mitigate single-metric variability.
• AI-driven Algorithms: Co-founder Abhinav Agarwal, with experience in noninvasive continuous glucose monitoring, developed core algorithms for interpreting hormonal signals, achieving 94.1% accuracy in early cycle phase classification.

The catch: While Clair Health addresses a critical gap in women’s health, it enters a competitive wearable market with established players like WHOOP, Oura, and Fitbit, which are increasingly adding women’s health features. The company’s success hinges on demonstrating superior accuracy and user adoption compared to existing, albeit less comprehensive, solutions, and navigating regulatory pathways for a medical device.